← All organizations
Highest phase reached
Phase 3
First clinical trial
Feb 1, 2004Last known activity
May 10, 2017
Acquired by Molecular Templates on Mar 17, 2017
Timeline
2000s
- Jun 1, 2001
Threshold Pharmaceuticals— Founded
2010s
- Mar 17, 2017
Molecular Templates— Acquired By
Drugs by trial phase (16 distinct, 32 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenoma, Islet Cell
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Gastrointestinal Stromal Tumors
- Hyperplasia
- Hypersensitivity
- Hypoxia
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Neoplasms
- Lung Neoplasms
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Neoplasms, Plasma Cell
- Neuroendocrine Tumors
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Hyperplasia
- Sarcoma
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
Recent trials (34)
- NCT03098160Lead sponsorPhase 1May 10, 2017
- NCT02712567CollaboratorN/AMar 9, 2016
- NCT02598687CollaboratorPhase 1Dec 1, 2015
- NCT02449681Lead sponsorPhase 2Aug 1, 2015
- NCT02454842Lead sponsorPhase 2Jun 1, 2015
- NCT02402062CollaboratorPhase 2Feb 1, 2015
- NCT02255110CollaboratorPhase 2Dec 1, 2014
- NCT01721941CollaboratorPhase 1Dec 1, 2014
- NCT02093962Lead sponsorPhase 2Jun 1, 2014
- NCT02093962Study chairPhase 2Jun 1, 2014
- NCT02076230CollaboratorPhase 1Feb 1, 2014
- NCT02047500CollaboratorPhase 1Jan 1, 2014
- NCT02020226Lead sponsorPhase 1Nov 1, 2013
- NCT01864538Study directorPhase 2May 1, 2013
- NCT01864538Lead sponsorPhase 2May 1, 2013
Details
- Founded
- South San Francisco, CA, US Jun 1, 2001
- Last known activity
- May 10, 2017